A Registered Cohort Study on α-Synucleinopathy

NCT05527067 · tracked via the Priya Life Science China tracker

Sponsor

Fujian Medical University Union Hospital

Phase

Observational

Started

2021-09-01

Last updated

2023-03-23

Condition(s) studied

α-synucleinopathy

Investigational drug(s) / intervention(s)

Data collectionData collection

Data collection: Neuropsychological assessment, brain MRI, electroencephalogram and biomarker datas will be collected

Study summary

α-Synucleinopathy is a cluster of neurodegenerative disease with motor and non-motor symptom. The data to be collected is intended to help healthcare providers make important medical decisions concerning α-synucleinopathy, through an enhanced understanding of the natural history, progression and multi-omics datasets of α-synucleinopathy.

Eligibility

Sex

ALL

Min age

30 Years

Max age

80 Years

Healthy volunteers

Accepted

Inclusion Criteria: * Participants with a clinical diagnosis of primary α-synucleinopathy * Unrelated healthy controls Exclusion Criteria: * Patients with secondary α-synucleinopathy that cannot be excluded. * Patients with other neurological disorders. * Pregnant or lactating women.

Primary outcome measure(s)

UPDRS /UMSARS scores — Baseline
Disease severity was evaluated by the neurologist using the united Parkinson's disease rating scale (UPDRS) or united multiple system atrophy rating scale (UMSARS) separately as diagnosed.

Trial sites (1)

Facility	City	Region	Status
Fujian Medical University Union Hospital	Fuzhou	Fujian	Recruiting

More Fujian Medical University Union Hospital trials in China

A Study of RC48-ADC Combined With JS001 for Advanced Extramammary Paget Disease of the Scrotum Recruiting

Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC Recruiting

Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC Recruiting

A Multimodal Convergent Cohort of Parkinson's Disease at FJMUUH (FJMUUH-PD): Natural History Study Starting soon

Ultra-stable Iodized Oil-Chemo Embolization Seq Thermal Ablation in Early Liver Ca Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05527067 on ClinicalTrials.gov ↗ ← All trials in China